Legend Biotech Corp ADR (LEGN) Stock Price, Quote & News

Company Profile

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candida...

Industry: Biotechnology

Sector: Healthcare

Phone: 737 317 5050

Website: www.legendbiotech.com

Address:

2101 Cottontail Lane, Somerset, United States

Bornjever Jan. 13 at 9:31 PM

$LEGN this is insane as the one billion plus sales numbers have been hit but earn is not till early March but company is already planning on expanding sales and rumors of their demise are not to be found but on Etrade I found almost 400 thousand shares purchased already and I admit it that almost 86,000 are scared but this is so obvious that some folks have made a lot of money making folks scared but come the money to be made on the way price goes up and I would expect these folks will cash in outrageously as they have done on the way down. GLTA but this is easy money to buy in the 20 dollar up to mid 30 dollar range quite nicely.

0 · Reply

HawkSetATL Jan. 13 at 9:06 PM

$LEGN 1,000 volume on the May $22.50c

0 · Reply

Tigerpicko Jan. 12 at 1:20 PM

$LEGN https://finance.yahoo.com/news/legend-biotech-highlights-recent-business-130000178.html

0 · Reply

Tigerpicko Jan. 9 at 9:59 PM

$LEGN just started ✅

0 · Reply

Tigerpicko Jan. 9 at 6:38 PM

$LEGN More bullish recommendations again today, just more news coming out positive, must say playing out exactly as predicted be great in March / April back to correct valuation

0 · Reply

HawkSetATL Jan. 9 at 5:00 PM

$LEGN holding since $40...

0 · Reply

Theflash88 Jan. 8 at 7:02 PM

$LEGN Lots of patience needed for this one.. I’ll wait for it to rocket this year.

0 · Reply

Bornjever Jan. 8 at 1:56 PM

$LEGN some very rich folks have been shorting this down to 20.00 and analysts rate it a buy with 10 buys and one hold but early March should confirm revenue of 1 billion plus and price 40-50 per share. These folks have lots of money to ride train all the way down and up for max cash out but looks like time to start buying in low 20-30 range.

0 · Reply

lebranjames Jan. 8 at 12:39 AM

$LEGN hoping I caught the bounce off $21

1 · Reply

Tigerpicko Jan. 7 at 5:27 PM

$LEGN coming around to the market leaders understanding 2026 is the year become profitable beyond any predictions, will continue to increase day by day with 14th being dramatic then through to March when 2025 full year and forecasts for the remaining quarters in 2026 through to 2027, will continue to increase 5% then drop 2% until it reaches more realistic value of $40 $STOCKTWITS

0 · Reply

Top 3 Health Care Stocks You'll Regret Missing This Quarter

INSM TEM

Dec 9, 2025, 3:31 PM EST - 5 weeks ago

Cancer Study Buoys These Small Biotechs

ACLX TERN

Dec 6, 2025, 2:00 PM EST - 5 weeks ago

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

Nov 25, 2025, 2:38 PM EST - 7 weeks ago

Legend Biotech: Is Carvykti Changing Cancer Treatment Forever?

Nov 13, 2025, 12:08 PM EST - 2 months ago

Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

Nov 12, 2025, 12:51 PM EST - 2 months ago

Legend Biotech Corporation (LEGN) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 11:05 AM EST - 2 months ago

Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Oct 29, 2025, 8:00 AM EDT - 2 months ago

Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results

Oct 10, 2025, 6:36 PM EDT - 3 months ago

US FDA adds boxed warning to J&J, Legend Biotech's cancer therapy

JNJ

Oct 6, 2025, 1:29 PM EDT - 3 months ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BIIB BMY

Sep 9, 2025, 11:47 PM EDT - 4 months ago

Legend Biotech Corporation (LEGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 18, 2025, 8:00 AM EDT - 5 months ago

Legend Biotech Appoints Carlos Santos as Chief Financial Officer

Aug 14, 2025, 2:12 PM EDT - 5 months ago

Legend Biotech: Q2 Record Sales Undermined By Losses, Immature Pipeline - Rating Downgrade

Aug 11, 2025, 1:41 PM EDT - 5 months ago

Legend Biotech Corporation (LEGN) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 7:00 AM EDT - 5 months ago

Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights

Jun 4, 2025, 6:10 PM EDT - 7 months ago

Mizuho's Jared Holz details potential biotech, pharma acquisitions

INSM VRNA

Jun 3, 2025, 10:45 AM EDT - 8 months ago

Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting

May 22, 2025, 5:15 PM EDT - 8 months ago

Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT

May 13, 2025, 11:15 AM EDT - 8 months ago

Legend Biotech Corporation (LEGN) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:00 AM EDT - 8 months ago

Legend Biotech Reports First Quarter 2025 Results and Recent Highlights

Apr 8, 2025, 2:59 PM EDT - 10 months ago

Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst

Mar 11, 2025, 12:06 PM EDT - 11 months ago

Legend Biotech Corporation (LEGN) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 7:00 AM EDT - 11 months ago

Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

Jan 7, 2025, 3:40 PM EST - 1 year ago

Top 5 Commercial Biotech Buyout Candidates: Legend Biotech (No. 4)

Dec 19, 2024, 8:01 AM EST - 1 year ago

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

$CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma$

Dec 9, 2024, 7:35 PM EST - 1 year ago

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

Dec 5, 2024, 2:14 PM EST - 1 year ago

Legend Biotech: The Story Brightens

Nov 12, 2024, 2:45 PM EST - 1 year ago

Legend Biotech Corporation (LEGN) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:30 AM EST - 1 year ago

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 5, 2024, 9:10 AM EST - 1 year ago

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

Nov 4, 2024, 7:30 AM EST - 1 year ago

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

Oct 4, 2024, 8:00 AM EDT - 1 year ago

Stock Picks From Seeking Alpha's September 2024 New Analysts

AME CCL CRWD CUK DVN EGO EMR

Oct 3, 2024, 7:41 AM EDT - 1 year ago

Legend Biotech to set up new R&D facility in Philadelphia

Oct 3, 2024, 7:30 AM EDT - 1 year ago

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

Sep 30, 2024, 9:47 AM EDT - 1 year ago

Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients

JNJ

Sep 27, 2024, 4:35 PM EDT - 1 year ago

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

Sep 24, 2024, 9:00 AM EDT - 1 year ago

Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech

Sep 18, 2024, 6:39 AM EDT - 1 year ago

Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion

Aug 20, 2024, 8:00 AM EDT - 1 year ago

Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Bornjever Jan. 13 at 9:31 PM

0 · Reply

HawkSetATL Jan. 13 at 9:06 PM

$LEGN 1,000 volume on the May $22.50c

0 · Reply

Tigerpicko Jan. 12 at 1:20 PM

$LEGN https://finance.yahoo.com/news/legend-biotech-highlights-recent-business-130000178.html

0 · Reply

Tigerpicko Jan. 9 at 9:59 PM

$LEGN just started ✅

0 · Reply

Tigerpicko Jan. 9 at 6:38 PM

$LEGN More bullish recommendations again today, just more news coming out positive, must say playing out exactly as predicted be great in March / April back to correct valuation

0 · Reply

HawkSetATL Jan. 9 at 5:00 PM

$LEGN holding since $40...

0 · Reply

Theflash88 Jan. 8 at 7:02 PM

$LEGN Lots of patience needed for this one.. I’ll wait for it to rocket this year.

0 · Reply

Bornjever Jan. 8 at 1:56 PM

0 · Reply

lebranjames Jan. 8 at 12:39 AM

$LEGN hoping I caught the bounce off $21

1 · Reply

Tigerpicko Jan. 7 at 5:27 PM

0 · Reply

trader_q Jan. 7 at 4:46 PM

$LEGN something is brewing. This is going much higher.

1 · Reply

jewell69 Jan. 7 at 4:32 PM

$LEGN lost a whopping 85.77 on $LEGN today s 90 at 01/07/2026 Sell Trade Details LEGN LEGEND BIOTECH CORP FUNSPONSORED ADR 1 ADR REPS 2 ORD SHS 45 $22.2371 $0.01 $1,000.66 01/07/2026 Sell Trade Details LEGN LEGEND BIOTECH CORP FUNSPONSORED ADR 1 ADR REPS 2 ORD SHS 45 $22.2407 $0.01 $1,000.82 cost basis on some shares were 24.14 on 12/9 Indeed, I traded it back/forth a bit with these final results -85.77 take home. I just had 2 bail cuz it is up tons today 1/7/26. got it ?

0 · Reply

Tigerpicko Jan. 7 at 4:28 PM

$LEGN $STOCKTWITS Oppenheimer's Review of Legend Biotech Current Rating and Price Target Rating: Outperform Price Target: $75 Oppenheimer has initiated coverage of Legend Biotech, highlighting its potential for growth. The firm believes that Legend is currently undervalued compared to its peers. Key Product Product: Carvykti Indication: Multiple myeloma Carvykti is a CAR-T therapy that has shown strong sales performance, surpassing other CAR-T products. Oppenheimer expects this product to drive Legend Biotech towards profitability in 2026. Market Position Despite market concerns affecting Legend's stock price, Oppenheimer's analysis suggests that the company is well-positioned for future success. The firm emphasizes that the current trading price is near its all-time low, indicating a potential for recovery and growth. This review reflects Oppenheimer's confidence in Legend Biotech's capabilities and market potential, particularly with its leading product, Carvykti.

0 · Reply

trader_q Jan. 7 at 4:06 PM

$LEGN could be looking at $25 today, anything is possible with reversal of a beaten down stock.

0 · Reply

trader_q Jan. 7 at 4:04 PM

$LEGN making epic move to the upside today.

0 · Reply

Tigerpicko Jan. 7 at 3:58 PM

$CGEN $JBIO $LEGN $STOCKTWITS

0 · Reply

Tigerpicko Jan. 7 at 3:57 PM

$LEGN

0 · Reply

HawkSetATL Jan. 7 at 3:47 PM

$LEGN Oppenheimer initiated coverage of Legend Biotech (LEGN) with an Outperform rating and $75 price target The firm notes the company commercializes Carvykti, a multiple-myeloma CAR-T therapy whose sales surpass all CARTs across all indications and are expected to deliver Legend profitability in 2026. Despite Carvykti’s notable growth, Oppenheimer believes Legend is the most undervalued company among 11 relevant peers and trading near its all-time low price, largely due to market concerns around potential competition from Anito-cel and Dara-Tec. Acknowledging Anito-cel/Dara-Tec competitiveness, the firm thinks market concerns are overdone, and Legend risk/reward is significantly skewed to the upside.

1 · Reply

trader_q Jan. 7 at 3:45 PM

$LEGN going to explode, volume picking up.

1 · Reply

notreload_ai Jan. 7 at 3:23 PM

$LEGN , $JBIO , $CGEN ... Oppenheimer and H.C. Wainwright start coverage on Legend Biotech, Jade Biosciences, and Compugen with bullish ratings and price targets, highlighting growth potential in CAR-T therapy, autoimmune, and immuno-oncology pipelines. https://notreload.xyz/oppenheimer-hc-wainwright-bullish-on-leg-jbio-cgen/

0 · Reply

johsmith Jan. 6 at 4:05 PM

$LEGN hold. Still waiting for prizes < $20

0 · Reply

smartkarma Jan. 6 at 3:22 PM

$LEGN | Primer: Legend Biotech Corp (LEGN US) - Jan 2026 "Legend Biotech is a commercial-stage biotechnology company whose value is primarily driven by its sole commercial product, Carvykti..." - αSK (Smartkarma) Read more: https://www.smartkarma.com/insights/primer-legend-biotech-corp-legn-us-jan-2026

1 · Reply

Market Cap	4.38B
Revenue (ttm)	627.24M
Net Income (ttm)	-177.03M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	45.94
Profit Margin	-28.22%
Debt to Equity Ratio	0.31

Volume	2,294,500
Avg Vol	2,175,866
Day's Range	N/A - N/A
Shares Out	184.69M
Stochastic %K	60%
Beta	0.12
Analysts	Strong Sell
Price Target	$72.41